These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35976170)

  • 21. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
    Keiser MF; Patel AB; Altan M
    Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution.
    Edwards CL; Comito F; Agraso Busto S; Harland C; Turajlic S; Larkin J; Heelan K; Fearfield L
    Clin Exp Dermatol; 2021 Mar; 46(2):338-341. PubMed ID: 33010053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment.
    Sugawara A; Koga H; Abe T; Ishii N; Nakama T
    J Dermatol; 2021 Mar; 48(3):401-404. PubMed ID: 33184934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients.
    Tong J; Kartolo A; Yeung C; Hopman W; Baetz T
    Curr Oncol; 2022 Oct; 29(10):7953-7963. PubMed ID: 36290906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy.
    Yamaguchi A; Saito Y; Narumi K; Furugen A; Takekuma Y; Shinagawa N; Shimizu Y; Dosaka-Akita H; Sugawara M; Kobayashi M
    J Cancer Res Clin Oncol; 2023 Apr; 149(4):1659-1666. PubMed ID: 36346501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
    Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
    Zhao JJ; Wen XZ; Ding Y; Li DD; Zhu BY; Li JJ; Weng DS; Zhang X; Zhang XS
    Aging (Albany NY); 2020 Jun; 12(11):10663-10675. PubMed ID: 32516130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series.
    Morris LM; Lewis HA; Cornelius LA; Chen DY; Rosman IS
    J Cutan Pathol; 2020 Aug; 47(8):742-746. PubMed ID: 32196722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
    Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
    Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma.
    Singh V; Chu Y; Gupta V; Zhao CW
    Cureus; 2020 Jun; 12(6):e8395. PubMed ID: 32637277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors.
    Holstead RG; Kartolo BA; Hopman WM; Baetz TD
    Melanoma Res; 2021 Jun; 31(3):258-263. PubMed ID: 33904518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
    Patel AB; Farooq S; Welborn M; Amaria RN; Chon SY; Diab A; Glitza Oliva IC; Huen AO; Li SQ; Nelson KC; Pacha O; Patel SP; Rapini RP; Tawbi HA; Wong MK; McQuade J; Davies MA; Haydu LE
    Cancer; 2022 Mar; 128(5):975-983. PubMed ID: 34724197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid.
    Zhang X; Sui D; Wang D; Zhang L; Wang R
    Front Immunol; 2021; 12():731774. PubMed ID: 34594337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
    Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
    Owen CN; Bai X; Quah T; Lo SN; Allayous C; Callaghan S; Martínez-Vila C; Wallace R; Bhave P; Reijers ILM; Thompson N; Vanella V; Gerard CL; Aspeslagh S; Labianca A; Khattak A; Mandala M; Xu W; Neyns B; Michielin O; Blank CU; Welsh SJ; Haydon A; Sandhu S; Mangana J; McQuade JL; Ascierto PA; Zimmer L; Johnson DB; Arance A; Lorigan P; Lebbé C; Carlino MS; Sullivan RJ; Long GV; Menzies AM
    Ann Oncol; 2021 Jul; 32(7):917-925. PubMed ID: 33798657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis.
    Song SJ; Song YK; Jang M; Shin E; Suh SY; Cho YS; Lee JY; Oh JM
    Target Oncol; 2023 Jan; 18(1):147-158. PubMed ID: 36515782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.